Nanodelivery and Nanodiagnostics for Nucleic Acids

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1854

Special Issue Editor

Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia
Interests: material chemistry; drug delivery; nucleic acid delivery; nanobiotechnology

Special Issue Information

Dear Colleagues,

Nucleic-acid-based macromolecules, including plasmid DNA, messenger RNA (mRNA) and small interfering RNA (siRNA), have attracted increasing attention due to having various functional sequences with use in a wide range of applications, such as cancer therapy, infection treatment and diseases diagnosis. However, nucleic acids suffer from intrinsic limits, e.g., a negative charge hindering cellular uptake and a fragile structure prone to degradation. Currently, viral and non-viral systems are mainly used for nucleic acid delivery and detection. However, viral vectors suffer from unwanted immunogenicity and cytotoxicity. Recent advances in nanotechnology have provided solutions to such challenges by making use of these materials’ controlled structures and functionalities, which provide unique advantages in achieving enhanced delivery or detection performance.

This Special Issue aims to cover latest advances in the field of nanotechnology-enhanced delivery and detection of nucleic acids and to bring together multidisciplinary researchers to present their work to a broad readership. We invite reviews and original articles on all aspects of “Nanotechnology-Enhanced Delivery and Detection of Nucleic Acids".

Dr. Yue Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • porous and mesoporous materials
  • gene transfection
  • nucleic acid delivery
  • nucleic acid detection
  • diseases diagnosis
  • delivery systems

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2818 KiB  
Article
Virus-like Silica Nanoparticles Improve Permeability of Macromolecules across the Blood–Brain Barrier In Vitro
by Yuran Feng, Yuxue Cao, Zhi Qu, Taskeen Iqbal Janjua and Amirali Popat
Pharmaceutics 2023, 15(9), 2239; https://doi.org/10.3390/pharmaceutics15092239 - 30 Aug 2023
Cited by 3 | Viewed by 1590
Abstract
The presence of the blood–brain barrier (BBB) limits the delivery of therapies into the brain. There has been significant interest in overcoming the BBB for the effective delivery of therapies to the brain. Inorganic nanomaterials, especially silica nanoparticles with varying surface chemistry and [...] Read more.
The presence of the blood–brain barrier (BBB) limits the delivery of therapies into the brain. There has been significant interest in overcoming the BBB for the effective delivery of therapies to the brain. Inorganic nanomaterials, especially silica nanoparticles with varying surface chemistry and surface topology, have been recently used as permeation enhancers for oral protein delivery. In this context, nanoparticles with varying sizes and surface chemistries have been employed to overcome this barrier; however, there is no report examining the effect of nanoscale roughness on BBB permeability. This paper reports the influence of nanoscale surface roughness on the integrity and permeability of the BBB in vitro, using smooth surface Stöber silica nanoparticles (60 nm) compared to rough surface virus-like silica nanoparticles (VSNP, 60 nm). Our findings reveal that VSNP (1 mg/mL) with virus-mimicking-topology spiky surface have a greater effect on transiently opening endothelial tight junctions of the BBB than the same dose of Stöber silica nanoparticles (1 mg/mL) by increasing the FITC-Dextran (70 kDa) permeability 1.9-fold and by decreasing the trans-endothelial electrical resistance (TEER) by 2.7-fold. This proof-of-concept research paves the way for future studies to develop next-generation tailored surface-modified silica nanoparticles, enabling safe and efficient macromolecule transport across the BBB. Full article
(This article belongs to the Special Issue Nanodelivery and Nanodiagnostics for Nucleic Acids)
Show Figures

Graphical abstract

Back to TopTop